๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Entecavir

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 4 trials in our China register that name Entecavir as an intervention. Synced 24 Sep 2026
4Trials tracked
2Recruiting now
3Lead sponsors
1Country register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Entecavir is named as a drug or biological intervention in 4 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Sun Yat-sen University (2), Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) and Third Affiliated Hospital, Sun Yat-Sen University (1). Registered phases: Phase 3, Observational and Phase 2. Conditions studied include Chronic Hepatitis B; Chronic Hepatitis b; Resolved Hepatitis B.

01

Clinical trials of Entecavir

4 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06966232 Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers (ClinicalTrials.gov ↗)
Gastrointestinal Cancers
Phase 3 Recruiting Sun Yat-sen University China
NCT02883647 Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b (ClinicalTrials.gov ↗)
Chronic Hepatitis b
Observational Recruiting Third Affiliated Hospital, Sun Yat-Sen University China
NCT07797231 Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response (ClinicalTrials.gov ↗)
Chronic Hepatitis B
Phase 3 Not yet open Chia Tai Tianqing Pharmaceutical Group Co., Ltd. China
NCT05453435 Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) (ClinicalTrials.gov ↗)
Resolved Hepatitis B, CD20 Positive B-cell Lymphoma
Phase 2 Active, closed Sun Yat-sen University China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

5 conditions
Condition (as registered)Trials
Chronic Hepatitis B1
Chronic Hepatitis b1
Resolved Hepatitis B1
CD20 Positive B-cell Lymphoma1
Gastrointestinal Cancers1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Sun Yat-sen University2
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1
Third Affiliated Hospital, Sun Yat-Sen University1
04

Trials by country register

RegisterEntecavir trials
Clinical trials in China4

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Entecavir works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Entecavir (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.